Citius Pharmaceuticals, Inc. CTXR
Cranford, New Jersey, is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care
products, with a focus on oncology, anti-infectives in adjunct cancer care and unique prescription products. Our goal generally is to
achieve leading market positions by providing therapeutic products that address unmet medical needs yet have a lower development risk
than usually is associated with new chemical entities. New formulations of previously approved drugs with substantial existing safety
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $90.0K | $90.0K | $90.0K | $90.0K | $75.0K | $50.0K | — |
| Cost of revenue | — | — | — | — | — | — | — | $75.0K | $50.0K | $45.0K |
| Gross profit | — | — | — | — | — | — | — | $0 | $0 | — |
| R&D | $9.2M | $11.9M | $14.8M | $17.7M | $12.2M | $8.8M | $8.6M | $6.6M | $2.9M | $2.9M |
| SG&A | $18.5M | $18.2M | $15.3M | $11.8M | $9.8M | $8.1M | $6.3M | $6.4M | $6.1M | $3.8M |
| Total operating expenses | $38.5M | $42.0M | $36.7M | $33.3M | $23.5M | $17.7M | $15.6M | $13.8M | $10.0M | $7.4M |
| Operating income | -$38.5M | -$42.0M | -$36.7M | -$33.3M | -$23.5M | -$17.7M | -$15.6M | -$13.8M | -$10.0M | -$7.4M |
| Interest expense | $267.8K | — | — | — | $10.8K | $15.7K | $16.4K | $15.8K | $850.8K | $9.0K |
| Pre-tax income | -$38.7M | -$38.8M | -$32.0M | -$33.1M | -$23.1M | -$17.5M | -$15.6M | $12.5M | $10.4M | -$8.3M |
| Income tax | $1.1M | $576.0K | $576.0K | $576.0K | $1.2K | $741 | — | — | — | — |
| Net income | -$39.7M | -$39.4M | -$32.5M | -$33.6M | -$23.1M | -$17.5M | -$15.6M | -$12.5M | -$10.4M | -$8.3M |
| EPS, basic | -3.38 | -5.97 | -5.57 | -0.23 | -0.23 | — | — | — | — | — |
| EPS, diluted | -3.38 | -5.97 | -5.57 | -0.23 | -0.23 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 |
| Shares, diluted (wtd. avg.) | $11.1M | $6.7M | $6.1M | $146.1M | $108.6M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.3M | $3.3M | $26.5M | $41.7M | $70.1M | $13.9M | $7.9M | $9.2M | $3.2M | $294.4K |
| Inventory | $22.3M | $8.3M | — | — | — | — | — | — | — | — |
| Total current assets | $27.9M | $14.2M | $34.4M | $44.6M | $72.8M | $14.0M | $7.9M | $10.1M | $3.4M | $892.8K |
| Property, plant and equipment | — | — | $1.4K | $4.1K | $7.0K | $1.6K | $590 | $1.5K | $3.2K | $3.7K |
| Goodwill | $9.3M | $9.3M | $9.3M | $9.3M | $9.3M | $9.3M | $9.3M | $1.6M | $1.6M | $1.6M |
| Total assets | $130.9M | $116.7M | $103.6M | $114.0M | $142.4M | $43.8M | $36.7M | $31.1M | $24.4M | $22.0M |
| Accounts payable | $13.7M | $4.9M | $2.9M | $1.2M | $1.3M | $1.9M | $2.7M | $1.6M | $602.4K | $909.2K |
| Total current liabilities | $44.9M | $35.8M | $5.8M | $4.5M | $4.0M | $4.1M | $4.6M | $3.2M | $2.5M | $5.2M |
| Total liabilities | $53.4M | $42.5M | $12.2M | $10.6M | $9.6M | $10.1M | $9.6M | — | — | — |
| Retained earnings | -$238.8M | -$201.4M | -$162.2M | -$129.7M | -$96.0M | -$70.6M | -$53.0M | -$40.3M | -$27.7M | -$17.3M |
| Total equity | $67.6M | $70.1M | $91.4M | $103.4M | $132.8M | $33.7M | $27.2M | $30.6M | $21.9M | $16.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$26.6M | -$28.2M | -$29.1M | -$28.4M | -$24.3M | -$16.9M | -$12.4M | -$11.3M | -$8.0M | -$5.9M |
| Depreciation and amortisation | — | $1.4K | $2.7K | $2.9K | $1.5K | $844 | $893 | $1.8K | $2.6K | $1.3K |
| Stock-based compensation | $10.8M | $11.8M | $6.6M | $3.9M | $1.5M | $803.3K | $716.0K | $779.7K | $986.6K | $732.2K |
| Capital expenditure | — | — | — | — | $6.9K | $1.8K | — | — | $2.1K | — |
| Investing cash flow | -$5.8M | -$5.0M | — | — | -$40.0M | -$1.8K | — | — | -$2.1K | $255.7K |
| Financing cash flow | $33.3M | $10.0M | $13.8M | — | $120.5M | $22.9M | $11.1M | $17.3M | $10.9M | $5.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-008861.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |